{"id":"truvada-or-epzicom-kivexa","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Insomnia"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Depression"}]},"_chembl":{"chemblId":"CHEMBL5970128","moleculeType":null,"molecularWeight":"607.73"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TRUVADA contains emtricitabine and tenofovir disoproxil fumarate, which are nucleoside reverse transcriptase inhibitors (NRTIs). EPZICOM/KIVEXA contains abacavir and lamivudine, which are also NRTIs. These medications work by blocking the reverse transcriptase enzyme, preventing the virus from replicating.","oneSentence":"TRUVADA and EPZICOM/KIVEXA are antiretroviral medications used to treat HIV-1 infection by inhibiting viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:53.026Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older"},{"name":"Prevention of HIV-1 infection in adults at high risk"}]},"trialDetails":[{"nctId":"NCT02275780","phase":"PHASE3","title":"Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-12-01","conditions":"HIV-1","enrollment":769},{"nctId":"NCT02246998","phase":"PHASE4","title":"Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-15","conditions":"HIV-1 Infection","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12002,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TRUVADA™ or EPZICOM™/KIVEXA™","genericName":"TRUVADA™ or EPZICOM™/KIVEXA™","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TRUVADA and EPZICOM/KIVEXA are antiretroviral medications used to treat HIV-1 infection by inhibiting viral replication. Used for Treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older, Prevention of HIV-1 infection in adults at high risk.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}